Clinical Trial Results

Long-Term Survival Data for Olaparib Maintenance in Ovarian Cancer Show Clinically Meaningful BoostBookmark

Cancer Network reports results from 5 years of follow up for a clinical trial in which the drug olaparib (Lynparza) was given to people who had already been treated for relapsed, high-grade serous, or endometrioid ovarian cancer—including primary peritoneal or fallopian tube cancer. Overall survival data show that olaparib outperformed a placebo drug for these patients, suggesting the possibility that it could be an effective “maintenance therapy.”

.

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction CancerBookmark

An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.

.

Efficacy and Safety of Sorafenib Plus Vitamin K Treatment for Hepatocellular CarcinomA: A Phase II, Randomized StudyBookmark

This scientific research paper published in the journal Cancer Medicine reports that the drug sorafenib has shown some effectiveness against hepatocellular carcinoma in a clinical trial, and that adding vitamin K2 enhanced that effectiveness.

.

For Esophageal Cancer, Immunotherapy Likely to Play Larger RoleBookmark

A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

.

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular CarcinomaBookmark

This academic research paper from The New England Journal of Medicine reports results from a clinical trial in which a treatment that combines the drugs atezolizumab and bevacizumab improved both progression-free and overall survival for people with unresectable primary liver cancer.

.

Innovent Biologics’s TYVYT/Byvasda combo shows survival benefit in late-stage liver cancer studyBookmark

Article from Seeking Alpha curated by Contributing Editor George Lundberg, MD, who notes: 

In a phase 3 clinical trial, a new drug combination improved both overall survival and progression-free survival for people with hepatocellular carcinoma.

.

Preliminary Results of Two Large Immune Therapy Studies Show Promise in Advanced Cervical CancerBookmark

Press release from Ohio State University Wexner Medical Center curated by Contributing Editor George Lundberg, MD.

This press release outlines promising preliminary results from two phase 2 clinical trials testing the drug balstilimab alone or in combination with zalifrelimab.

.

Maintenance Avelumab Improves Survival in Advanced Bladder CancerBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial for certain patients with advanced urothelial carcinoma, overall survival was prolonged by about 30% by using supportive care plus maintenance treatment with the drug avelumab, versus supportive care alone.

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

In a First, Proton Therapy Bests Radiotherapy in an RCTBookmark

Article from Medscape curated by Editor in Chief George Lundberg, MD, who notes: 

In a clinical trial that compared proton beam therapy with standard radiotherapy for esophageal cancer, the two treatments were found to be virtually identical in terms of progression-free survival, overall survival, and quality of life.

Go to full news article published by Medscape.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

ATIM-14. Results of Phase II Clinical Trial of Oncolytic Herpes Virus G47∆ in Patients with GlioblastomaBookmark

Research paper from Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

In a phase 2 clinical trial, glioblastoma patients were treated with a herpes virus that has been genetically engineered to kill cancer cells. The genetically engineered virus is injected directly into patients’ brain tumors. It is early and the numbers are small, but the trial produced amazing results compared to historical controls.

Go to full paper published in Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.